Associated tags: Eye, Application, Patient, MDAX, Quality of life, TecDAX, Carin, Microsurgery, Carl Zeiss AG, ZEISS, Surgeon, Research
Locations: US, KOREA, UNITED STATES, SWITZERLAND, FLORIDA, AUSTRIA, NEW YORK, DISTRICT OF COLUMBIA, PARIS, FRANKREICH, DEUTSCHLAND, DEUTSCHLAND, CHINA, OKLAHOMA, USA, ITALIEN, SPANIEN, APAC, INDIEN, CALIFORNIA, GERMANY, CA, EUROPE, MA, ASIA, CANADA
Retrieved on:
Donnerstag, März 28, 2024
Glaucoma,
Nomogram,
ASCRS,
Patient,
Eye,
SCI,
Astigmatism,
Surgeon,
Workflow,
3D,
Cataract,
HDR,
LVC,
Biostatistics,
Health,
Food,
2D,
Bed,
Digital,
Near-sightedness,
Sharp HealthCare,
FDA,
Movement,
LASIK,
Temperature,
SMILE,
Refractive surgery,
RGB,
News,
Silicon,
Workplace,
Society,
Retina,
Human,
Telescopic sight Product News: ZEISS announces enhanced visualization capabilities with the new ZEISS ARTEVO 850 3D heads-up ophthalmic microscope.
Key Points:
- Product News: ZEISS announces enhanced visualization capabilities with the new ZEISS ARTEVO 850 3D heads-up ophthalmic microscope.
- Spatial Computing Innovation: ZEISS will demonstrate a digital application for experiencing 3D videos and more on the Apple Vision Pro.
- ZEISS is extending its workflow offerings with new surgical and visualization technologies at ASCRS.
- At ASCRS, surgeons are invited to join the ZEISS SMILE Speed Competition in lenticule extraction with the new ZEISS VISUMAX 800.
Retrieved on:
Donnerstag, März 28, 2024
Glaucoma,
Nomogram,
ASCRS,
Patient,
Eye,
SCI,
Astigmatism,
Surgeon,
Workflow,
3D,
Cataract,
HDR,
LVC,
Biostatistics,
Health,
Food,
2D,
Bed,
Digital,
Near-sightedness,
Sharp HealthCare,
FDA,
Movement,
LASIK,
Temperature,
SMILE,
Refractive surgery,
RGB,
News,
Silicon,
Workplace,
Society,
Retina,
Human,
Telescopic sight Product News: ZEISS announces enhanced visualization capabilities with the new ZEISS ARTEVO 850 3D heads-up ophthalmic microscope.
Key Points:
- Product News: ZEISS announces enhanced visualization capabilities with the new ZEISS ARTEVO 850 3D heads-up ophthalmic microscope.
- Spatial Computing Innovation: ZEISS will demonstrate a digital application for experiencing 3D videos and more on the Apple Vision Pro.
- ZEISS is extending its workflow offerings with new surgical and visualization technologies at ASCRS.
- At ASCRS, surgeons are invited to join the ZEISS SMILE Speed Competition in lenticule extraction with the new ZEISS VISUMAX 800.
Carl Zeiss Meditec,
Quartal,
Umsatz,
Euro,
VJ,
Wachstum,
Auftragseingang,
Ergebnis,
Zins,
Steuern,
Vertriebskanal,
Auslieferung,
Arbeitsplan,
Business,
Unit,
SBU,
Region,
EMEA,
Amerika,
Lateinamerika,
Entwicklung,
Markt,
Verbrauchsmaterial,
Rohertrag,
Druck,
Wert,
Gewinn,
Aktie,
Erholung
Carl Zeiss Meditec generated revenue of €475.0m in the first quarter of fiscal year 2023/24 (prior year: €470.3m), corresponding to a growth of +1.0% (adjusted for currency effects: +3.3%).
Key Points:
- Carl Zeiss Meditec generated revenue of €475.0m in the first quarter of fiscal year 2023/24 (prior year: €470.3m), corresponding to a growth of +1.0% (adjusted for currency effects: +3.3%).
- Dr. Markus Weber, President and CEO of Carl Zeiss Meditec AG commented on the Q1 results: “We have made a solid start to the new fiscal year.
- The strategic business unit Microsurgery achieved revenue growth of +10.6% (adjusted for currency effects: +13.7%) to €123.9m (prior year: €112.0m).
- The APAC [2] region recorded a slight decline in revenue of -0.9% (adjusted for currency effects: +0.4%), to €206.4m (prior fiscal year: €208.2m).
Retrieved on:
Donnerstag, Februar 1, 2024
Multimedia,
United States district court,
DICOM,
Harmony,
General counsel,
HFA,
DNA,
Patient,
District court,
Decoder,
Carl Zeiss Meditec DUBLIN, Calif., Feb. 1, 2024 /PRNewswire/ -- Carl Zeiss Meditec AG announced today that it has reached a favorable resolution with Topcon to settle its lawsuit against the Japanese company's U.S.-based subsidiaries that had been pending in U.S. federal court for the Northern District of California. The settlement reinforces the protection of ZEISS's trade secrets and restores a level playing field for fair competition. The lawsuit asserted that Topcon had illicitly obtained stolen ZEISS files that included highly confidential information. Previously, the court had issued a preliminary injunction against Topcon, and more recently denied Topcon's motion for summary judgment on ZEISS's claims of trade secret misappropriation. Jury trial had been set to begin in February 2024.
Key Points:
- Landmark legal settlement protects customers, patients and the company's extensive digital innovation in ophthalmology
DUBLIN, Calif., Feb. 1, 2024 /PRNewswire/ -- Carl Zeiss Meditec AG announced today that it has reached a favorable resolution with Topcon to settle its lawsuit against the Japanese company's U.S.-based subsidiaries that had been pending in U.S. federal court for the Northern District of California.
- The lawsuit asserted that Topcon had illicitly obtained stolen ZEISS files that included highly confidential information.
- According to the lawsuit filed by Carl Zeiss Meditec AG's U.S. subsidiary, beginning in 2018 Topcon illegally obtained stolen ZEISS files.
- The case is Carl Zeiss Meditec, Inc. v. Topcon Medical Systems, Inc., Topcon Healthcare Solutions, Inc., et al., United States District Court, Northern District of California, Oakland Division (case no.
Digital technology,
Bed,
Patient,
Nomogram,
MD,
Astigmatism,
Near-sightedness,
Quality of life,
SMILE,
Food,
Hertz,
FDA,
Surgeon The updated ZEISS femtosecond laser provides U.S. refractive surgeons with faster treatment, greater flexibility, and significant workflow enhancements.
Key Points:
- The updated ZEISS femtosecond laser provides U.S. refractive surgeons with faster treatment, greater flexibility, and significant workflow enhancements.
- ZEISS Medical Technology announced today that the U.S. Food and Drug Administration (FDA) has approved the VISUMAX® 800 with SMILE® pro software from ZEISS for surgically treating nearsightedness, with or without astigmatism.
- With these workflow enhancements along with greater flexibility and faster treatment, the VISUMAX® 800 with SMILE® pro software from ZEISS offers substantial market opportunities for U.S. surgeons.
- For more information about the VISUMAX® 800 with SMILE® pro software from ZEISS, visit www.zeiss.com/us/visumax-800 .
Generation,
Zeiss,
Femtosekundenlaser,
Arbeitsablauf,
Medizintechnik,
Zulassung,
Software,
Behandlung,
Kurzsichtigkeit,
Astigmatismus,
U.S.,
Druck,
Administration,
FDA,
Zeitpunkt,
Markt,
Auge,
SMILE,
Verfahren,
Menschen,
Fehlsichtigkeit,
Leiter,
Global,
Sales,
Augenheilkunde,
Modul (Software),
Chirurgie,
Technologie,
Unternehmen,
Patient,
Ergebnis,
Hause,
Doktor,
S.,
Erkenntnis,
Hertz (Einheit),
Sekunde,
Praxis,
Krankenhaus,
Zentrierung,
System,
Drehung,
Datenerfassung,
Analyse,
Vorhersagbarkeit,
Information,
Webseite
Retrieved on:
Donnerstag, Januar 11, 2024
Digital technology,
Bed,
Patient,
Nomogram,
MD,
Astigmatism,
Near-sightedness,
Quality of life,
SMILE,
Food,
Hertz,
FDA,
Surgeon DUBLIN, Calif. and JENA, Germany, Jan. 11, 2024 /PRNewswire/ -- Carl Zeiss Meditec AG -- ZEISS Medical Technology announced today that the U.S. Food and Drug Administration (FDA) has approved the VISUMAX® 800 with SMILE® pro software from ZEISS for surgically treating nearsightedness, with or without astigmatism. The latest generation of femtosecond lasers from ZEISS enters the U.S. market at a time when more than 8 million eyes have been treated with SMILE worldwide, reflecting the technology's broad global momentum driven by strong adoption in Asia and Europe.
Key Points:
- DUBLIN, Calif. and JENA, Germany, Jan. 11, 2024 /PRNewswire/ -- Carl Zeiss Meditec AG -- ZEISS Medical Technology announced today that the U.S. Food and Drug Administration (FDA) has approved the VISUMAX® 800 with SMILE® pro software from ZEISS for surgically treating nearsightedness, with or without astigmatism.
- The VISUMAX® 800 with SMILE® pro software from ZEISS enables faster treatment, creating the lenticule in less than 10 seconds thanks to a faster laser pulse repetition rate of 2 MHz.
- With these workflow enhancements along with greater flexibility and faster treatment, the VISUMAX® 800 with SMILE® pro software from ZEISS offers substantial market opportunities for U.S. surgeons.
- For more information about the VISUMAX® 800 with SMILE® pro software from ZEISS, visit www.zeiss.com/us/visumax-800 .
Retrieved on:
Donnerstag, Januar 11, 2024
Digital technology,
Bed,
Patient,
Nomogram,
MD,
Astigmatism,
Near-sightedness,
Quality of life,
SMILE,
Food,
Hertz,
FDA,
Surgeon DUBLIN, Calif. and JENA, Germany, Jan. 11, 2024 /PRNewswire/ -- Carl Zeiss Meditec AG -- ZEISS Medical Technology announced today that the U.S. Food and Drug Administration (FDA) has approved the VISUMAX® 800 with SMILE® pro software from ZEISS for surgically treating nearsightedness, with or without astigmatism. The latest generation of femtosecond lasers from ZEISS enters the U.S. market at a time when more than 8 million eyes have been treated with SMILE worldwide, reflecting the technology's broad global momentum driven by strong adoption in Asia and Europe.
Key Points:
- DUBLIN, Calif. and JENA, Germany, Jan. 11, 2024 /PRNewswire/ -- Carl Zeiss Meditec AG -- ZEISS Medical Technology announced today that the U.S. Food and Drug Administration (FDA) has approved the VISUMAX® 800 with SMILE® pro software from ZEISS for surgically treating nearsightedness, with or without astigmatism.
- The VISUMAX® 800 with SMILE® pro software from ZEISS enables faster treatment, creating the lenticule in less than 10 seconds thanks to a faster laser pulse repetition rate of 2 MHz.
- With these workflow enhancements along with greater flexibility and faster treatment, the VISUMAX® 800 with SMILE® pro software from ZEISS offers substantial market opportunities for U.S. surgeons.
- For more information about the VISUMAX® 800 with SMILE® pro software from ZEISS, visit www.zeiss.com/us/visumax-800 .
Retrieved on:
Samstag, Dezember 30, 2023
Carl Zeiss Meditec,
Umsatz,
Euro,
VJ,
Wachstum,
Ergebnis,
Zins,
Steuern,
Wert,
Rand,
Prozent,
Prognose,
Bereich,
Forschung,
Abweichung,
Entwicklung,
Business,
Unit,
SBU,
Plus,
Marktwachstum,
Region,
EMEA,
Amerika,
Vertrieb,
Marketing,
Abbau,
Vertriebskanal,
Augenheilkunde,
Markt,
Intraokularlinse,
Niveau,
Investition
